Cook Andrew D, Visvanathan Kumar
Cooperative Research Centre for Chronic Inflammatory Diseases, Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Victoria, 3010, Australia.
Expert Opin Ther Targets. 2004 Oct;8(5):375-90. doi: 10.1517/14728222.8.5.375.
There are a large number of diseases involving inappropriate activation of the immune system. This review focuses on one such disease, rheumatoid arthritis (RA). Over recent years there has been a dramatic shift in the treatment of RA, in which biological agents, such as monoclonal antibodies and immuno-fusion proteins, have offered the potential to enhance or replace conventional immunosuppressive therapies. This review covers some of the novel biological molecules currently under investigation as potential therapeutic targets in RA. In addition, it covers the genomic and proteomic strategies being used to identify potential new molecular targets for future therapies. Selectively blocking the immune response, in a combination approach blocking not only inflammation but also the adaptive memory response and tissue destruction, holds great promise for the treatment of RA and many other immune-mediated diseases.
有大量疾病涉及免疫系统的不适当激活。本综述聚焦于其中一种疾病——类风湿性关节炎（RA）。近年来，RA的治疗发生了巨大转变，生物制剂，如单克隆抗体和免疫融合蛋白，为增强或替代传统免疫抑制疗法提供了可能。本综述涵盖了目前作为RA潜在治疗靶点正在研究的一些新型生物分子。此外，还涵盖了用于识别未来治疗潜在新分子靶点的基因组和蛋白质组学策略。以联合方法选择性阻断免疫反应，不仅阻断炎症，还阻断适应性记忆反应和组织破坏，对RA及许多其他免疫介导疾病的治疗具有巨大前景。
